<DOC>
	<DOCNO>NCT02239003</DOCNO>
	<brief_summary>NMDA neurotransmission play important role learn memory . NMDA receptor find decrease frontal lobe hippocampus mild cognitive impairment . This study randomize , double-blind , placebo-controlled drug trial . All subject allocate randomly 2 group : ( 1 ) NMDA-enhancer : DAOIB group ( start dose : 250-500 mg/d ) ; ( 2 ) placebo group . The study period 24 week . The investigator hypothesize DAOIB may yield good efficacy placebo cognitive function patient mild cognitive impairment .</brief_summary>
	<brief_title>NMDA-enhancing Agent Treatment Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Clinical diagnosis mild cognitive impairment MMSE 1726 CDR 0.5 Hachinski Ischemic Score &gt; 4 Substance abuse/dependence Parkinson disease , epilepsy , dementia psychotic feature Major depressive disorder Major physical illness Severe visual hearing impairment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>